Bioxodes SA, a company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces it has been selected to present at key international business and scientific conferences this spring and early summer:
- Bioxodes to give presentation at Bio€quity (May 14-16) and present posters at ESOC (May 24-26) and ISTH (June 24-28)
- Company prepares Series A extension funding round for upcoming phase IIa and preparation of phase IIb clinical trials
Gosselies, Belgium, April 26, 2023 – Bioxodes SA, a company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces it has been selected to present at key international business and scientific conferences this spring and early summer: Bio€quity on May 14-16, in Dublin, Ireland, the European Stroke Organisation Conference (ESOC) on May 24-26, in Munich, Germany, and the International Society on Thrombosis and Haemostasis (ISTH) congress on June 24-28, in Montreal, Canada.
“We are thrilled to participate in these key events to present the progress of our first-in-class drug candidate, Ir-CPI, for patients with IntraCerebral Hemorrhage (ICH),” said Marc Dechamps, CEO of Bioxodes. “There is currently a major unmet medical need, with no treatment option that can prevent acute secondary brain damage within the first 72 hours in patients exhibiting this pathology. We are working on our Series A funding round to help finance our phase IIa clinical trial for Ir-CPI and to be fully ready for the start of phase IIb.”
Bio€quity – May 14-16, Dublin
This meeting is Europe’s premier international showcase for financial dealmakers and biopharma executives to meet innovative biotech companies.
Marc Dechamps, CEO of Bioxodes, will give a presentation as part of the ‘Autoimmune, Inflammation and Thrombosis’ track.
The presentation, titled: ‘Bioxodes, a clinical stage company developing a first-in-class drug candidate against thrombosis and neuroinflammation starting with Hemorrhagic Stroke’, will be held in the Liffey meeting room on May 15, at 11:18am IST. The presentation will also be available on BioCentury’s partneringONE® platform.
ESOC – May 24-26, Munich
ESOC is Europe’s leading forum for advances in research and clinical care of patients with cerebrovascular diseases.
Charlotte Corbisier, clinical project manager at Bioxodes, will give the presentation, titled ‘Bioxodes: start-up company’s approach to a phase IIa trial on Ir-CPI’, on May 23, 2:59pm to 5pm CEST, at the International Congress Center in Munich as part of the pre-ESOC day organized by the European Stroke Organisation Trials Alliance (ESOTA).
During ESOC, Valérie Pireaux, preclinical scientist at Bioxodes, will be presenting an e-poster titled ‘Ir-CPI reduces brain infiltration of neutrophils releasing extracellular traps and attenuates neuronal degeneration after intracerebral hemorrhage’. This will be presented during the e-posters section at the International Congress Center.
ISTH – June 24-28, Montreal
ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and hemostasis.
At the congress, Valérie Pireaux will be presenting a poster titled ‘Evaluation of hemorrhage and edema expansion, including effect on neutrophil-mediated neuroinflammation in intracerebral hemorrhage, using Ir-CPI, a thromboinflammation inhibitor’.
The poster will be presented on June 26, between 6:30pm and 7:30pm ET, at the Exhibition Hall of the Palais des Congrès.
Each poster will be available on Bioxodes’ website after each event.
About Ir-CPI
Ir-CPI is a first-in-class drug candidate. Thanks to its unique mode of action, it prevents both the formation of unwanted blood clots and any increased risks of bleeding (action on factors XIa and XIIa). By inhibiting neutrophils activation, it also prevents the acute neuroinflammatory events associated with intracerebral hemorrhage. Derived from a tick’s saliva, this product could become the first injectable antithrombotic drug suitable for use in patients within the first 72 hours of intracerebral hemorrhage. The market for an injectable form of such a molecule, primarily for use in hospitals, is estimated to be worth more than one billion dollars per annum.
About Bioxodes
Bioxodes specializes in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since it was founded in 2013, Bioxodes has developed its own flagship program based around its Ir-CPI molecule. Ir-CPI is a first-in-class drug candidate aimed at patients with thromboinflammatory disease. The company, which is based in Gosselies in Belgium, has so far secured €22.1 million in funding from Belgian investment funds and business angels, including €8.5 million in non-dilutive funding from the Wallonia region. Bioxodes holds both granted and pending patents associated with Ir-CPI in the European Union and the United States.
Press and Analyst Contacts
Andrew Lloyd and Associates
Emilie Chouinard / Saffiyah Khalique
emilie@ala.associates / saffiyah@ala.associates
UK +44 1273 952 481
US +1 203 724 5950